Search hospitals > Ontario > LONDON

London Health Sciences Centre

Claim this profile
LONDON, Ontario N6A 5W9
Global Leader in Prostate Cancer
Global Leader in Cancer
Conducts research for Crohn's Disease
Conducts research for Heart Failure
Conducts research for Ulcerative Colitis
616 reported clinical trials
60 medical researchers
Photo of London Health Sciences Centre in LONDONPhoto of London Health Sciences Centre in LONDONPhoto of London Health Sciences Centre in LONDON

Summary

London Health Sciences Centre is a medical facility located in LONDON, Ontario. This center is recognized for care of Prostate Cancer, Cancer, Crohn's Disease, Heart Failure, Ulcerative Colitis and other specialties. London Health Sciences Centre is involved with conducting 616 clinical trials across 732 conditions. There are 60 research doctors associated with this hospital, such as Michael Chu, MD, Vipul Jairath, Brent Lanting, MD, and Terry Ponich, MD, FRCPC.

Area of expertise

1Prostate Cancer
Global Leader
London Health Sciences Centre has run 36 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I
2Cancer
Global Leader
London Health Sciences Centre has run 31 trials for Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Top PIs

Clinical Trials running at London Health Sciences Centre

Crohn's Disease
Chronic Kidney Disease
Heart Failure
Lung Cancer
Heart Disease
Cardiovascular Disease
Cancer
Obesity
Stroke
Atrial Fibrillation
Image of trial facility.

Vedolizumab

for Ulcerative Colitis and Crohn's Disease

The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Recruiting3 awards Phase 3
Image of trial facility.

Vedolizumab + Adalimumab/Ustekinumab

for Crohn's Disease

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A. Each participant will be followed up for at least 26 weeks after the last dose of treatment.
Recruiting3 awards Phase 410 criteria
Image of trial facility.

Guselkumab

for Pediatric Crohn's Disease

This trial tests guselkumab, an anti-inflammatory medication, on children with Crohn's Disease who initially responded well to it. The goal is to see if the benefits last over several months by reducing immune system activity. Guselkumab has shown effectiveness in treating moderate-to-severe psoriasis and psoriatic arthritis.
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at London Health Sciences Centre?
Where is London Health Sciences Centre located?
Who should I call to ask about financial aid or insurance network?
What insurance does London Health Sciences Centre accept?
What awards or recognition has London Health Sciences Centre received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security